BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang HC, Tsou HH, Pei SN, Chang CS, Chen JH, Yao M, Lin SJ, Lin J, Yuan Q, Xia N, Liu TW, Chen PJ, Cheng AL, Hsu C;  Taiwan Cooperative Oncology Group. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J Hepatol. 2018;69:286-292. [PMID: 29551710 DOI: 10.1016/j.jhep.2018.02.033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang W, Jia R, Gao Y, Liu J, Luan J, Qiao F, Liu L, Zhang X, Wang F, Fu J. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients. Front Immunol 2022;13:894410. [DOI: 10.3389/fimmu.2022.894410] [Reference Citation Analysis]
2 Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, Testoni B, Van Bömmel F, Andrisani O, Beumont-Mauviel M, Block TM, Chan HLY, Cloherty GA, Delaney WE, Geretti AM, Gehring A, Jackson K, Lenz O, Maini MK, Miller V, Protzer U, Yang JC, Yuen MF, Zoulim F, Revill PA. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35859026 DOI: 10.1038/s41575-022-00649-z] [Reference Citation Analysis]
3 Lok J, Dusheiko G, Carey I, Agarwal K. Review article: Novel biomarkers in hepatitis B infection. Aliment Pharmacol Ther 2022. [PMID: 35770458 DOI: 10.1111/apt.17105] [Reference Citation Analysis]
4 Fujita M, Kusumoto S, Ishii I, Iwata T, Fujisawa T, Sugiyama M, Hata A, Mizokami M. Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma. Sci Rep 2022;12:7365. [PMID: 35513395 DOI: 10.1038/s41598-022-10665-3] [Reference Citation Analysis]
5 Ye J, Xie P, Zhou Z, Sun Y, Wang F, You Y, Teng J, Yang C, Zhang X, Han Y. Protective Role of Rheumatic Diseases Against Hepatitis B Virus Infection and Human Leukocyte Antigen B27 Highlighted. Front Med (Lausanne) 2022;9:814423. [PMID: 35223909 DOI: 10.3389/fmed.2022.814423] [Reference Citation Analysis]
6 Cerva C, Salpini R, Alkhatib M, Malagnino V, Piermatteo L, Battisti A, Bertoli A, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Ferrari L, Laura C, Teti E, Cantonetti M, Arcese W, Ceccherini-silberstein F, Perno C, Andreoni M, Svicher V, Sarmati L. Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines 2022;10:443. [DOI: 10.3390/biomedicines10020443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Vanwolleghem T, Adomati T, Van Hees S, Janssen HL. Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV. JHEP Reports 2022;4:100398. [DOI: 10.1016/j.jhepr.2021.100398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chang Y, Jeong SW, Jang JY. Hepatitis B Virus Reactivation Associated With Therapeutic Interventions. Front Med (Lausanne) 2021;8:770124. [PMID: 35096867 DOI: 10.3389/fmed.2021.770124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wang L, Li L, Li C, Hou Y, Xu M, Yu Y, Ni X, Wang R, Wang H, Wang L, Peng J, Hou M. Significance of anti-HBc serological status in primary immune thrombocytopenia. Br J Haematol 2021. [PMID: 34854079 DOI: 10.1111/bjh.17977] [Reference Citation Analysis]
10 Lee JH, Kim HS. Current laboratory tests for diagnosis of hepatitis B virus infection. Int J Clin Pract 2021;:e14812. [PMID: 34487586 DOI: 10.1111/ijcp.14812] [Reference Citation Analysis]
11 Pei SN, Liu YF, Kuo CY, Wang MC, Ma MC, Liao CK, Ng HY, Chen CH. Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab. Leuk Lymphoma 2021;:1-8. [PMID: 34323157 DOI: 10.1080/10428194.2021.1948034] [Reference Citation Analysis]
12 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Zhou JY, Song LW, Yuan R, Lu XP, Wang GQ. Prediction of hepatic inflammation in chronic hepatitis B patients with a random forest-backward feature elimination algorithm. World J Gastroenterol 2021; 27(21): 2910-2920 [PMID: 34135561 DOI: 10.3748/wjg.v27.i21.2910] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Vachon A, Osiowy C. Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management. Viruses 2021;13:951. [PMID: 34064049 DOI: 10.3390/v13060951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Risk factors for de novo hepatitis B during solid cancer treatment. World J Clin Cases 2020; 8(24): 6264-6273 [PMID: 33392307 DOI: 10.12998/wjcc.v8.i24.6264] [Reference Citation Analysis]
16 Shoji T, Kanamori M, Inoue J, Saito R, Osada Y, Shimoda Y, Chonan M, Uenohara H, Masamune A, Tominaga T. Hepatitis B virus reactivation during temozolomide administration for malignant glioma. Int J Clin Oncol 2021;26:305-15. [PMID: 33118116 DOI: 10.1007/s10147-020-01814-7] [Reference Citation Analysis]
17 Li FC, Li YK, Fan YC. Biomarkers for hepatitis B virus replication: an overview and a look to the future. Expert Rev Gastroenterol Hepatol 2020;14:1131-9. [PMID: 32887529 DOI: 10.1080/17474124.2020.1815530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rybicka M, Bielawski KP. Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection. Microorganisms. 2020;8. [PMID: 32942584 DOI: 10.3390/microorganisms8091416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
19 Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, Hershman DL, Loehrer AP, Sabichi AL, Symington BE, Terrault N, Wong ML, Somerfield MR, Artz AS. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.J Clin Oncol. 2020;38:3698-3715. [PMID: 32716741 DOI: 10.1200/JCO.20.01757] [Cited by in Crossref: 17] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
20 Caviglia GP. Role of immunoglobulin indexes in patients with chronic hepatitis B. Minerva Med 2020;111:382-3. [PMID: 32700865 DOI: 10.23736/S0026-4806.20.06787-7] [Reference Citation Analysis]
21 Liu W, Huang W, Wang M, Lv R, Li J, Wang Y, Deng S, Yi S, Liu H, Rao Q, Xu Y, Lv L, Qiu L, Zou D, Wang J. Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy. Br J Haematol 2020;191:126-9. [PMID: 32671820 DOI: 10.1111/bjh.16951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
22 Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol 2020;14:565-78. [PMID: 32448008 DOI: 10.1080/17474124.2020.1774364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed? Clin Liver Dis. 2020;24:317-333. [PMID: 32620274 DOI: 10.1016/j.cld.2020.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
24 Xiao W, Zhou Y, Yu P, Yang A, Zheng S, Tang H, Xie X. Prognostic value of chronic hepatitis B virus infection in patients with breast cancer in a hepatitis B virus endemic area. Ann Transl Med 2020;8:180. [PMID: 32309327 DOI: 10.21037/atm.2020.01.97] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Wu T, Wu N, Ma YX, Wu J, Gao Y, Pan XB. Role of hepatitis B antibody in predicting reactivation of resolved hepatitis B virus infection in leukemia patients. Antiviral Res 2020;177:104765. [PMID: 32171856 DOI: 10.1016/j.antiviral.2020.104765] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Cornberg M, Lok AS, Terrault NA, Zoulim F, Berg T, Brunetto MR, Buchholz S, Buti M, Chan HL, Chang K, Dandri M, Dusheiko G, Feld JJ, Ferrari C, Ghany M, Janssen HL, Kennedy P, Lampertico P, Liang J, Locarnini S, Maini MK, Mishra P, Papatheodoridis G, Petersen J, Schlottmann S, Wang S, Wedemeyer H. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology 2020;72:539-57. [DOI: 10.1016/j.jhep.2019.11.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 93] [Article Influence: 30.0] [Reference Citation Analysis]
27 Vanwolleghem T, Groothuismink ZMA, Kreefft K, Hung M, Novikov N, Boonstra A. Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV. J Hepatol 2020;73:52-61. [PMID: 32061650 DOI: 10.1016/j.jhep.2020.01.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
28 Caviglia GP, Olivero A, Ciancio A, Tandoi F, Troshina G, Rosso C, Abate ML, Younes R, Ribaldone DG, Smedile A, Rizzetto M, Romagnoli R, Saracco GM, Bugianesi E. Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. Diagn Microbiol Infect Dis 2020;96:114985. [PMID: 32008810 DOI: 10.1016/j.diagmicrobio.2020.114985] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
29 Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology 2019. [PMID: 31713892 DOI: 10.1002/hep.31030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
30 Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019;11. [PMID: 31717647 DOI: 10.3390/v11111049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
31 Yang HC, Kao JH. Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus. Gut 2019;68:2095. [PMID: 30301771 DOI: 10.1136/gutjnl-2018-317385] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Wu Y, Wang X, Lin X, Shen C, Chen X. Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance. J Microbiol Immunol Infect 2021;54:238-44. [PMID: 31784245 DOI: 10.1016/j.jmii.2019.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Zannella A, Marignani M, Begini P. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. Viruses 2019;11:E858. [PMID: 31540124 DOI: 10.3390/v11090858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Höner Zu Siederdissen C, Maasoumy B, Cornberg M. New viral biomarkers for Hepatitis B: Are we able to change practice? J Viral Hepat 2018;25:1226-35. [PMID: 30187603 DOI: 10.1111/jvh.12993] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
35 Zhang YL, Gao Y, Cao JL, Zhao JH, Zhang TY, Yang CL, Xiong HL, Wang YB, Ou SH, Cheng T, Chen CR, Yuan Q, Xia NS. Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus. Emerg Microbes Infect 2019;8:724-33. [PMID: 31130075 DOI: 10.1080/22221751.2019.1619485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Svicher V, Salpini R, Malagnino V, Piermatteo L, Alkhatib M, Cerva C, Sarmati L. New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts. Viruses 2019;11:E783. [PMID: 31450680 DOI: 10.3390/v11090783] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
37 Yao Z, Liao W, Ho C, Chen K, Shih J, Chen J, Lin Z, Lin C, Yang JC, Yu C. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients. European Journal of Cancer 2019;117:107-15. [DOI: 10.1016/j.ejca.2019.05.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
38 Lee TH, Schiano TD. Hepatology Clearance for Immunomodulation in Patients With Hepatitis B. Clin Liver Dis (Hoboken) 2019;14:78-85. [PMID: 31508226 DOI: 10.1002/cld.757] [Reference Citation Analysis]
39 Nishida T, Matsubara T, Yakushijin T, Inada M. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers. Hepatol Int 2019;13:407-15. [PMID: 31290069 DOI: 10.1007/s12072-019-09966-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
40 Charre C, Levrero M, Zoulim F, Scholtès C. Non-invasive biomarkers for chronic hepatitis B virus infection management. Antiviral Res 2019;169:104553. [PMID: 31288041 DOI: 10.1016/j.antiviral.2019.104553] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
41 Tsou HH, Yang HC, Hsiao CF, Hsiung CA, Liu TW, Chuang MH, Wu HY, Hsu YT, Tsui CW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. J Formos Med Assoc 2020;119:335-44. [PMID: 31235201 DOI: 10.1016/j.jfma.2019.05.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
42 Pessoni GC, Marinho TA, Carneiro MMS, Martins RM, Soares CC, Silva LN, Matos MA, Arantes AM, Teles JA, Santos NC, Araujo Teles S. Hepatitis B virus infection among oncohematologic disease patients in Central Brazil: prevalence, risk factors and immunization. Hematol Transfus Cell Ther 2019;41:199-204. [PMID: 31036513 DOI: 10.1016/j.htct.2018.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
43 Liu JH, Liao XW, Chen CH, Yao M, Li CC, Lin CT, Tsai CH, Chou WC, Hou HA, Huang SY, Wu SJ, Chen YC, Tien HF, Tang JL, Ko BS. Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. Br J Haematol 2019;186:72-85. [PMID: 30919947 DOI: 10.1111/bjh.15884] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
44 Caviglia GP, Tandoi F, Olivero A, Saracco GM, Rizzetto M, Romagnoli R, Smedile A. Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. J Hepatol 2019;70:793-5. [PMID: 30591262 DOI: 10.1016/j.jhep.2018.11.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
45 Guo L, Wang D, Ouyang X, Tang N, Chen X, Zhang Y, Zhu H, Li X. Recent Advances in HBV Reactivation Research. Biomed Res Int. 2018;2018:2931402. [PMID: 30687740 DOI: 10.1155/2018/2931402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
46 Inuzuka T, Ueda Y, Arasawa S, Takeda H, Matsumoto T, Osaki Y, Uemoto S, Seno H, Marusawa H. Expansion of viral variants associated with immune escape and impaired virion secretion in patients with HBV reactivation after resolved infection. Sci Rep 2018;8:18070. [PMID: 30584239 DOI: 10.1038/s41598-018-36093-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
47 Guo YF, Pan JX, Zhuang WH. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome. Infect Agent Cancer 2018;13:40. [PMID: 30559832 DOI: 10.1186/s13027-018-0215-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
48 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy. Intern Med 2019;58:375-80. [PMID: 30210131 DOI: 10.2169/internalmedicine.1587-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
49 Chinese Society of Lymphoma, Chinese Anti-cancer Association., Chinese Society of Hematology, Chinese Medical Association. [The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)]. Zhonghua Xue Ye Xue Za Zhi 2021;42:441-6. [PMID: 34384148 DOI: 10.3760/cma.j.issn.0253-2727.2021.06.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]